Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes
Open Access
- 1 October 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (7), 848-854
- https://doi.org/10.1086/507543
Abstract
Background. Type 2 diabetes (DM) is a strong risk factor for tuberculosis (TB) and is associated with a slower response to TB treatment and a higherKeywords
This publication has 21 references indexed in Scilit:
- Risk factors for pulmonary tuberculosis in Russia: case-control studyBMJ, 2005
- Serum Concentrations of Antimycobacterial Drugs in Patients with Pulmonary Tuberculosis in BotswanaClinical Infectious Diseases, 2005
- Association between Acquired Rifamycin Resistance and the Pharmacokinetics of Rifabutin and Isoniazid among Patients with HIV and TuberculosisClinical Infectious Diseases, 2005
- Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2003
- Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projectionsDiabetes Care, 1998
- Risk Factors for Rifampin Mono-resistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Reduced Plasma Concentrations of Antituberculosis Drugs in Patients with HIV InfectionAnnals of Internal Medicine, 1997
- The Effects of Diabetes Mellitus on Pharmacokinetics and Pharmacodynamics in HumansClinical Pharmacokinetics, 1991
- HYPERGLYCAEMIA AND ABSORPTION OF SULPHONYLUREA DRUGSThe Lancet, 1989
- Diabetes mellitus and pulmonary tuberculosisJournal of Chronic Diseases, 1957